{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T01:57:25Z","timestamp":1775008645454,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clinbiochem.2023.110659","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T03:24:15Z","timestamp":1696389855000},"page":"110659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study"],"prefix":"10.1016","volume":"121-122","author":[{"given":"Mohamed H.Y.","family":"Bekheet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamiaa A.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasha H.","family":"Elkaffas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona A.","family":"Kamel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Elmonem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110659_b0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biology10050433","article-title":"An \u201cOmic\u201d Overview of Fragile X Syndrome","volume":"10","author":"Dionne","year":"2021","journal-title":"Biology"},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110659_b0010","first-page":"60","article-title":"Fragile X syndrome: clinical presentation, pathology and treatment","volume":"156","author":"Salcedo-Arellano","year":"2020","journal-title":"Gac. Med. Mex."},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110659_b0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ejhg.2014.185","article-title":"EMQN best practice guidelines for the molecular genetic testing and reporting of fragile X syndrome and other fragile X-associated disorders","volume":"23","author":"Biancalana","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110659_b0020","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ejmhg.2016.01.005","article-title":"Fragile X syndrome: Current insight","volume":"17","author":"Dean","year":"2016","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"16","key":"10.1016\/j.clinbiochem.2023.110659_b0025","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ajmg.a.32439","article-title":"Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey","volume":"146A","author":"Bailey","year":"2008","journal-title":"Am. J. Med. Genet. Part A"},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110659_b0030","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ridd.2014.01.032","article-title":"Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder","volume":"35","author":"Thurman","year":"2014","journal-title":"Res. Dev. Disabil."},{"issue":"7","key":"10.1016\/j.clinbiochem.2023.110659_b0035","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s10803-013-2013-6","article-title":"Symptoms of Autism in Males with Fragile X Syndrome: A Comparison to Nonsyndromic ASD Using Current ADI-R Scores","volume":"45","author":"McDuffie","year":"2015","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.clinbiochem.2023.110659_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1352\/1944-7558-115.6.461","article-title":"Seizures in fragile X syndrome: characteristics and comorbid diagnoses","volume":"115","author":"Berry-Kravis","year":"2010","journal-title":"Am. J. Intellect. Dev. Disabil."},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110659_b0045","first-page":"57","article-title":"Outcomes in Neurodevelopmental and Genetic Disorders","volume":"14","author":"Friedlander","year":"2005","journal-title":"Can Child Adolesc Psychiatr Rev."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0050","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuroscience.2016.01.021","article-title":"Regional brain volumes changes in adult male FMR1-KO mouse on the FVB strain","volume":"318","author":"Lai","year":"2016","journal-title":"Neurosci."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0055","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","article-title":"Fragile X syndrome","volume":"3","author":"Hagerman","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.clinbiochem.2023.110659_b0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fgene.2014.00355","article-title":"The fragile X syndrome-autism comorbidity: what do we really know?","volume":"5","author":"Abbeduto","year":"2014","journal-title":"Front. Genet."},{"issue":"Suppl 3","key":"10.1016\/j.clinbiochem.2023.110659_b0065","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1542\/peds.2016-1159F","article-title":"Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment","volume":"139","author":"Kaufmann","year":"2017","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110659_b0070","doi-asserted-by":"crossref","first-page":"a009886","DOI":"10.1101\/cshperspect.a009886","article-title":"Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities","volume":"4","author":"Zoghbi","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.clinbiochem.2023.110659_b0075","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/brainsci9010004","article-title":"Early Identification of Fragile X Syndrome through Expanded Newborn Screening","volume":"9","author":"Okoniewski","year":"2019","journal-title":"Brain Sci."},{"issue":"10","key":"10.1016\/j.clinbiochem.2023.110659_b0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrn4001","article-title":"Dysregulation and restoration of translational homeostasis in fragile X syndrome","volume":"16","author":"Richter","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"30","key":"10.1016\/j.clinbiochem.2023.110659_b0085","doi-asserted-by":"crossref","first-page":"9867","DOI":"10.1523\/JNEUROSCI.1162-14.2014","article-title":"Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model","volume":"34","author":"Sidhu","year":"2014","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.clinbiochem.2023.110659_b0090","doi-asserted-by":"crossref","first-page":"e26549","DOI":"10.1371\/journal.pone.0026549","article-title":"Reversal of fragile X phenotypes by manipulation of A\u03b2PP\/A\u03b2 levels in Fmr1KO mice","volume":"6","author":"Westmark","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110659_b0095","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuron.2015.06.032","article-title":"Dysregulated ADAM10-Mediated Processing of APP during a Critical Time Window Leads to Synaptic Deficits in Fragile X Syndrome","volume":"87","author":"Pasciuto","year":"2015","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110659_b0100","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mgg3.398","article-title":"Fragile X checklists: A meta\u2010analysis and development of a simplified universal clinical checklist","volume":"6","author":"Lubala","year":"2018","journal-title":"Molec Gen & Gen Med"},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110659_b0105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","article-title":"A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome","volume":"56","author":"Filipovic-Sadic","year":"2010","journal-title":"Clin. Chem."},{"issue":"18","key":"10.1016\/j.clinbiochem.2023.110659_b0110","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1073\/pnas.0509695103","article-title":"Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664","volume":"103","author":"Galvan","year":"2006","journal-title":"PNAS"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110659_b0115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J. Med. Genet."},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110659_b0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.biocel.2012.01.023","article-title":"MMP9: A novel function in synaptic plasticity","volume":"44","author":"Dziembowska","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0125","doi-asserted-by":"crossref","first-page":"9275204","DOI":"10.1155\/2016\/9275204","article-title":"Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology","volume":"2016","author":"Kurzepa","year":"2016","journal-title":"Dis. Markers"},{"key":"10.1016\/j.clinbiochem.2023.110659_b0130","doi-asserted-by":"crossref","first-page":"26052","DOI":"10.1038\/srep26052","article-title":"Finding novel distinctions between the sAPP \u03b1-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue","volume":"6","author":"Ray","year":"2016","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.clinbiochem.2023.110659_b0135","first-page":"271","article-title":"El Awady, Prevalence of fragile X syndrome among school-age Egyptian males. World","volume":"3","author":"Meguid","year":"2007","journal-title":"J. Pediatr."},{"issue":"10","key":"10.1016\/j.clinbiochem.2023.110659_b0140","doi-asserted-by":"crossref","first-page":"e110370","DOI":"10.1371\/journal.pone.0110370","article-title":"Triple test screening for Down syndrome: an Egyptian-tailored study","volume":"9","author":"Abou-Youssef","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110659_b0145","first-page":"237","article-title":"Frequency of fragile-x in x-linked mental retardation","volume":"9","author":"El Sobky","year":"2008","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"Suppl 3","key":"10.1016\/j.clinbiochem.2023.110659_b0150","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1542\/peds.2016-1159D","article-title":"Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families","volume":"139","author":"Wheeler","year":"2017","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.clinbiochem.2023.110659_b0155","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejmhg.2011.07.001","article-title":"Consanguineous matings among Egyptian population","volume":"12","author":"Shawky","year":"2011","journal-title":"Egypt. J. Med. Hum. Genet."},{"issue":"8","key":"10.1016\/j.clinbiochem.2023.110659_b0160","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","article-title":"High MMP-9 activity levels in fragile X syndrome are lowered by minocycline","volume":"161A","author":"Dziembowska","year":"2013","journal-title":"Am. J. Med. Genet. Part A"},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110659_b0165","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.celrep.2014.10.064","article-title":"Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes","volume":"9","author":"Gkogkas","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2377-10-91","article-title":"Open-label add-on treatment trial of minocycline in fragile X syndrome","volume":"10","author":"Paribello","year":"2010","journal-title":"BMC Neurol."},{"issue":"5","key":"10.1016\/j.clinbiochem.2023.110659_b0175","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1242\/dmm.008045","article-title":"Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase","volume":"4","author":"Siller","year":"2011","journal-title":"Dis. Model. Mech."},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110659_b0180","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/DBP.0b013e318287cd17","article-title":"A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome","volume":"34","author":"Leigh","year":"2013","journal-title":"J. Dev. Behavior. Pediatr."},{"issue":"11","key":"10.1016\/j.clinbiochem.2023.110659_b0185","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrn3320","article-title":"Huntley Synaptic circuit remodelling by matrix metalloproteinases in health and disease","volume":"13","author":"Huntley","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"issue":"10","key":"10.1016\/j.clinbiochem.2023.110659_b0190","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00702-020-02231-w","article-title":"Evidence supporting the role of telomerase, MMP-9, and SIRT1 in attention-deficit\/hyperactivity disorder (ADHD)","volume":"127","author":"Uzun Cicek","year":"2020","journal-title":"J Nneural. Transmis."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.neuropharm.2014.06.028","article-title":"Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials","volume":"88","author":"Braat","year":"2015","journal-title":"Neuropharmacol."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnint.2019.00049","article-title":"Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome","volume":"13","author":"McLane","year":"2019","journal-title":"Front. Integr. Neurosci."},{"issue":"11","key":"10.1016\/j.clinbiochem.2023.110659_b0205","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s10803-010-0988-9","article-title":"Brief report: acamprosate in fragile X syndrome","volume":"40","author":"Erickson","year":"2010","journal-title":"J. Autism. Dev. Dis."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpsychires.2014.07.011","article-title":"Impact of acamprosate on plasma amyloid-\u03b2 precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker","volume":"59","author":"Erickson","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.clinbiochem.2023.110659_b0215","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1371\/journal.pbio.0050052","article-title":"FMRP mediates mGluR5-dependent translation of amyloid precursor protein","volume":"5","author":"Westmark","year":"2007","journal-title":"PLoS Biol."},{"key":"10.1016\/j.clinbiochem.2023.110659_b0220","unstructured":"D.K. Lahiri, J.M. Long, B. Ray, D.K. Sokol, Biochemical evidence for the dysregulation of Alzheimer's amyloid precursor protein (APP) expression and metabolism in fragile X syndrome (FXS) and severe autism. F1000Posters. 2 (2011) 864 (poster) https:\/\/f1000research.com\/posters\/1597."},{"issue":"6","key":"10.1016\/j.clinbiochem.2023.110659_b0225","doi-asserted-by":"crossref","first-page":"e20405","DOI":"10.1371\/journal.pone.0020405","article-title":"Increased secreted amyloid precursor protein-\u03b1 (sAPP\u03b1) in severe autism: proposal of a specific, anabolic pathway and putative biomarker","volume":"6","author":"Ray","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clinbiochem.2023.110659_b0230","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2013.00094","article-title":"Autism as early neurodevelopmental disorder: evidence for an sAPP\u03b1-mediated anabolic pathway","volume":"7","author":"Lahiri","year":"2013","journal-title":"Front. Cell. Neurosci."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202300187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991202300187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:00:40Z","timestamp":1757865640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991202300187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":46,"alternative-id":["S000991202300187X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110659","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum matrix metalloproteinase-9 (MMP9) and amyloid-beta protein precursor (APP) as potential biomarkers in children with Fragile-X syndrome: A cross sectional study","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2023.110659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110659"}}